title: Tumor suppressor protein p53 negatively regulates human pregnane X receptor activity.
abstract: The human pregnane X receptor (PXR) regulates genes involved in drug metabolism and disposition. PXR associates with multiple corepressors that attenuate and coactivators that enhance its activity. PXR plays a vital role in the drug metabolism pathway, and a comprehensive examination of PXR-associated proteins will provide greater insight into the regulation of the receptor and possible therapeutic implications. We performed a mass spectrometric screen to identify PXR-associated proteins. Here we report that the tumor suppressor protein p53 can associate with PXR and downregulate its activity. A loss-of-function p53 mutant (R175H) interacts with PXR but does not repress its activity. Mutant p53 can relieve the suppressive effect of wild-type p53 by competing with its interaction with PXR, suggesting that protein-protein interaction is required but not sufficient for p53 to repress PXR activity. Interestingly, a PXR variant with a naturally occurring deletion of a conserved, unique sequence in the ligand binding domain (PXR174-210) did not interact with p53, indicating that the PXR-p53 interaction is specific. Using a chromatin immunoprecipitation assay, we showed that p53 inhibits the binding of PXR to the CYP3A4 promoter. The loss of p53 function in tumor cells leads to aberrant cell proliferation, apoptosis, carcinogenesis, and altered sensitivity to chemotherapeutic drugs, whereas PXR contributes to chemoresistance in many cancer cells. Our findings show for the first time that wild-type p53 can negatively regulate PXR by physically associating with it. Thus, PXR and p53 appear to play important yet opposing roles in the sensitivity of tumor cells to chemotherapy.
authors.affiliation: Department of Chemical Biology & Therapeutics, St. Jude Children's Research Hospital, Memphis, TN 38105-3678, USA.
authors.forename: Ayesha
authors.initials: A
authors.lastname: Elias
authors.forename: Jing
authors.initials: J
authors.lastname: Wu
authors.forename: Taosheng
authors.initials: T
authors.lastname: Chen
mesh_terms: D045744:Cell Line, Tumor; D051544:Cytochrome P-450 CYP3A / Q000235:genetics; D015536:Down-Regulation; D019008:Drug Resistance, Neoplasm; D057809:HEK293 Cells; D006801:Humans; D000077297:Pregnane X Receptor; D011401:Promoter Regions, Genetic; D060066:Protein Interaction Maps; D011987:Receptors, Steroid / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*
chemical_list: D000077297:Pregnane X Receptor; D011987:Receptors, Steroid; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human
references.citation: Expert Opin Drug Metab Toxicol. 2012 Jul;8(7):803-17
references.pmid: 22554043
references.citation: J Clin Invest. 2011 Aug;121(8):3220-32
references.pmid: 21747170
references.citation: Proc Natl Acad Sci U S A. 1992 May 15;89(10):4495-9
references.pmid: 1584781
references.citation: Cell Death Differ. 2006 Jun;13(6):1027-36
references.pmid: 16557269
references.citation: J Endocrinol. 2004 Mar;180(3):497-504
references.pmid: 15012604
references.citation: Toxicol Appl Pharmacol. 2004 Sep 15;199(3):251-65
references.pmid: 15364541
references.citation: Genes Dev. 1999 Dec 15;13(24):3198-208
references.pmid: 10617569
references.citation: Mol Pharmacol. 2006 Jan;69(1):99-108
references.pmid: 16219912
references.citation: Cancer Res. 2007 Nov 1;67(21):10361-7
references.pmid: 17974979
references.citation: FEBS Lett. 2006 Feb 6;580(3):890-3
references.pmid: 16427050
references.citation: Biochem Pharmacol. 2005 Mar 1;69(5):867-73
references.pmid: 15710363
references.citation: Cancer Res. 1995 Apr 15;55(8):1649-54
references.pmid: 7712469
references.citation: Drug Resist Updat. 2002 Oct;5(5):209-16
references.pmid: 12450786
references.citation: Nat Rev Cancer. 2009 Oct;9(10):724-37
references.pmid: 19776742
references.citation: Mol Cell Biol. 2004 Sep;24(18):7931-40
references.pmid: 15340055
references.citation: Mol Endocrinol. 2002 Feb;16(2):402-10
references.pmid: 11818510
references.citation: Neoplasia. 2007 Dec;9(12):1152-9
references.pmid: 18084622
references.citation: Genes Dev. 1998 Oct 15;12(20):3195-205
references.pmid: 9784494
references.citation: J Mol Biol. 2003 Aug 22;331(4):815-28
references.pmid: 12909012
references.citation: Drug Metab Dispos. 2002 Jul;30(7):795-804
references.pmid: 12065438
references.citation: Cancer Lett. 1997 Jun 24;116(2):191-6
references.pmid: 9215863
references.citation: Trends Biochem Sci. 2005 Feb;30(2):66-9
references.pmid: 15691650
references.citation: Endocr Rev. 2002 Oct;23(5):687-702
references.pmid: 12372848
references.citation: Drug Metab Rev. 2013 Feb;45(1):60-72
references.pmid: 23330542
references.citation: Science. 1992 May 8;256(5058):827-30
references.pmid: 1589764
references.citation: Oncogene. 1999 Jan 14;18(2):477-85
references.pmid: 9927204
references.citation: Cancer Res. 2009 Apr 15;69(8):3405-14
references.pmid: 19351845
references.citation: Cancer Lett. 2013 Jan 1;328(1):1-9
references.pmid: 22939994
references.citation: Cancer Cell. 2007 Oct;12(4):303-12
references.pmid: 17936556
references.citation: Science. 1998 Nov 20;282(5393):1497-501
references.pmid: 9822382
references.citation: FASEB J. 1993 Nov;7(14):1407-13
references.pmid: 8224613
references.citation: J Biol Chem. 2001 Oct 19;276(42):38472-9
references.pmid: 11504717
references.citation: Drug Metab Dispos. 2009 Jun;37(6):1295-304
references.pmid: 19251824
references.citation: Genes Dev. 1994 May 15;8(10):1235-46
references.pmid: 7926727
references.citation: Adv Cancer Res. 2000;77:81-137
references.pmid: 10549356
references.citation: Oncogene. 1994 Sep;9(9):2523-9
references.pmid: 8058315
references.citation: Oncogene. 2003 Oct 20;22(47):7486-95
references.pmid: 14576853
references.citation: J Biol Chem. 2008 Nov 7;283(45):30650-7
references.pmid: 18784074
references.citation: Genes Dev. 1998 May 1;12(9):1269-77
references.pmid: 9573044
references.citation: Mol Cancer. 2010 Mar 02;9:46
references.pmid: 20196838
references.citation: Annu Rev Pharmacol Toxicol. 2002;42:1-23
references.pmid: 11807162
references.citation: Science. 1991 Jul 5;253(5015):49-53
references.pmid: 1905840
references.citation: Clin Cancer Res. 1999 Aug;5(8):2103-7
references.pmid: 10473093
references.citation: Cancer Res. 1994 Nov 15;54(22):5824-30
references.pmid: 7954409